AbbVie Inc.ABBV
NYSE•Healthcare•Drug Manufacturers - General
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. (ABBV) reported trailing twelve months revenue of $62.82B as of March 2026, a 9.5% increase year-over-year. Quarterly revenue reached $15.00B, reflecting continued top-line momentum.
AbbVie Inc. generated $3.63B in TTM net income, with quarterly EBITDA of $5.93B. The operating margin contracted from 28.0% to 26.6%, suggesting rising cost pressures or pricing headwinds.
The spread between operating margin (26.6%) and net margin (4.6%) indicates significant non-operating expenses or interest burden. Net margin has narrowed from 9.6% a year ago, reflecting increased costs or interest expense.
ABBV trades at a P/E of 107.9x (a premium multiple) and a P/S of 6.2x.
The company generated $3.56B in free cash flow over the trailing twelve months, a 154.6% increase year-over-year, indicating strong cash generation ability. The balance sheet shows $136.46B in total assets with $64.53B in long-term debt against $-6.66B in stockholders equity. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are under pressure, averaging 21.2%. The business may lack pricing power or face rising costs.'
Consistently high ROE averaging 146.9% suggests a durable competitive advantage and efficient capital allocation.
Free cash flow is consistently positive and growing — a hallmark of a capital-light business that can self-fund growth.
TTM revenue has grown consistently (7 of 7 quarters up), with ~14.2% growth over the period. Strong demand durability.
Data-driven red flags and warnings across 21 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
FCF covers net income by -31.6x on average — earnings are well-supported by cash generation.
D/E ratio is 45.4 — dangerously high. The company is heavily leveraged and vulnerable to rising rates or cash flow dips.
Revenue is stable or growing over recent quarters — demand appears durable.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Share count is stable — no significant dilution or buyback activity.